Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
– Company to host live webcast and conference call Monday, December 15,…
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE…
NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
September 18, 2025 16:30 ET Â | Source: NovaBay Pharmaceuticals Inc. EMERYVILLE, Calif.,…